Comments on ‘An airway organoid-based screen identifies a role for the HIF1α‒glycolysis axis in SARS-CoV-2 infection’  

作　　者：Xiaohua Duan Hui Wang David D.Ho Robert E.Schwartz Todd Evans Shuibing Chen 

机构地区：[1]Department of Surgery,Weill Cornell Medicine,1300 York Ave.,New York,NY 10065,USA [2]State Key Laboratory of Oncogenes and Related Genes,Center for Single-Cell Omics,School of Public Health,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China [3]Aaron Diamond AIDS Research Center,Columbia University Vagelos College of Physicians and Surgeons,New York,NY 10032,USA [4]Division of Gastroenterology and Hepatology,Department of Medicine,Weill Cornell Medicine,1300 York Ave.,New York,NY 10065,USA [5]Department of Physiology,Biophysics and Systems Biology,Weill Cornell Medicine,1300 York Ave.,New York,NY 10065,USA

出　　处：《Journal of Molecular Cell Biology》2022年第1期60-61,共2页分子细胞生物学报（英文版）

摘　　要：Coronavirus disease 2019(COVID-19)has been an ongoing public health crisis since the end of 2019;besides vaccine development,there have been major research efforts focused on developing antiviral therapeutics.Remdesivir was the first US Food and Drug Administration(FDA)-approved antiviral drug for COVID-19.Subsequently,the FDA granted emergency use authorization(EUA)for three monoclonal antibody treatments,including sotrovimab or a combination of casirivimab and imdevimab,or bamlanivimab and etesevimab,each of which targets the coronavirus spike protein to block viral entry.Most recently,Britain granted conditional authorization for the ribonucleoside analog molnupiravir,developed by Merck as a viral replication inhibitor.The protease inhibitor PF-07321332 developed by Pfizer and boosted by ritonavir showed promising results in a phase III clinical trial,reducing the risk of hospitalization or death by 89%compared with placebo.

关 键 词：PFIZER MERCK VACCINE 

分 类 号：R373[医药卫生—病原生物学]